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Abstract: Chronic inflammation caused by infections has been suggested to be one of the most
important cause of cancers. It has recently been shown that there is correlation between intestinal
bacteria and cancer development including metastasis. As over 700 bacterial species exist in an oral
cavity, it has been concerning that bacterial infection may cause oral cancer. However, the role of
bacteria regarding tumorigenesis of oral cancer remains unclear. Several papers have shown that
Fusobacterium species deriving the oral cavities, especially, play a crucial role for the development of
colorectal and esophageal cancer. F. nucleatum is a well-known oral bacterium involved in formation
of typical dental plaque on human teeth and causing periodontal diseases. The greatest characteristic
of F. nucleatum is its ability to adhere to various bacteria and host cells. Interestingly, F. nucleatum
is frequently detected in oral cancer tissues. Moreover, detection of F. nucleatum is correlated with
the clinical stage of oral cancer. Although the detailed mechanism is still unclear, Fusobacterium species
have been suggested to be associated with cell adhesion, tumorigenesis, epithelial-to-mesenchymal
transition, inflammasomes, cell cycle, etc. in oral cancer. In this review, we introduce the reports
focused on the association of Fusobacterium species with cancer development and progression
including oral, esophageal, and colon cancers.
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1. Introduction
Oral cancer, predominantly oral squamous cell carcinoma (OSCC), is a significant health problem
and is regarded as the main cause of death from oral diseases in many countries. Traditional risk factors
of oral cancer include alcohol abuse, tobacco and tobacco-derivate chewing, and oral virus infections.
Other factors include infections, exposure to ionizing radiation, and environmental pollutants [1].
Thus, various causes of cancer are known to be closely involved in lifestyle choices, such as smoking,
drinking, and diet.
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Chronic inflammation caused by infections has been suggested to be one of the most important
cause of cancers [2]. Indeed, infection of various viruses, bacteria, and parasites, such as Hepatitis B
virus (HBV), Hepatitis B virus (HCV), Epstein–Barr virus (EBV), human papilloma virus (HPV), human
herpes virus 8 (HHV8), human thymus-derived-cell leukemia/lymphoma virus-1 (HTLV-1), human
immunodeficiency virus (HIV), Helicobacter pylori, Schistosomiasis, and liver flukes are well-known
causes of cancer [2]. Recently, commensal bacteria are also involved in carcinogenesis. A huge
number of different commensal bacteria naturally colonize in the human body in a relatively stable
equilibrium. Microbial-immune network correlates gut bacteria with the whole-body health, and
the failure of immune homeostasis manifests significant impact on various diseases, which might
result in cancer [3–5]. Indeed, some commensal bacteria including Peptostreptococcus anaerobius [6],
enterotoxigenic Bacteriodes fragiles [7], and Escherichia coli [8] are involved in carcinogenesis of colorectal
cancer (CRC).
In the oral cavity, bacteria, fungi, viruses, and archaea naturally colonize in different habitats
including the teeth, gingival sulcus, tongue, cheeks, hard and soft palates, and tonsils. The oral
microbiota refers to a highly varied and complicated ecosystem of these organisms. Over 700 bacterial
species are endemic to the oral cavity, and indigenous oral flora act to prevent the settlement of foreign
bacteria. Some bacteria of the oral cavity are harmful and can cause serious disease, while many of
the oral bacteria are in fact beneficial in preventing diseases. Thus, the oral cavity is inhabited by
complex multispecies bacterial communities that usually exist in a balanced immunoinflammatory
state with the host [9]. It is now established that many chronic inflammatory conditions are caused by
an imbalance between host–microbiota interactions, resulting in a dysbiotic community, deregulated
immune responses, and eventually disease outcomes [10]. Oral commensal bacteria play a critical role
in the development of oral diseases, including periodontal disease and tooth loss, and maintenance
of a normal oral physiological environment [11,12]. Moreover, oral commensal bacteria are known
to be involved in the pathogenesis and development of systematic diseases, such as pneumonia,
cardiovascular diseases, diabetes, dementia, etc. It has been of concern that oral commensal bacteria
may be involved in the pathogenesis of OSCC [13,14]. However, it remains unclear the role of bacteria
regarding carcinogenesis of OSCC, even though a lot of bacteria inhabit in the oral cavity. Interestingly,
it recently has been shown that one of oral commensal bacteria, Fusobacterium species, especially, play
a crucial role for the development of CRC [15–17]. As Fusobacterium species are commensal bacteria in
the oral cavity, the cumulative evidences of Fusobacterium species in CRC make us hypothesize that
Fusobacterium species may be involved in the pathogenesis and development of OSCC. In this review,
we introduce the reports focused on the association of Fusobacterium species with cancer development
and progression.
2. Fusobacterium Species
The genus Fusobacterium are Gram-negative, non-spore forming, non-motile, pleomorphic, and
obligate anaerobic bacilli, which inhabit the human oral cavity, oropharynx, upper respiratory,
gastrointestinal, and female genitourinary tracts as part of the normal flora [18]. Nine species
including F. nucleatum (subspecies nucleatum, polymorphum, vincentii, animalis, fusiforme, and canifelium),
F. necrophorum (subspecies necrophorum and funduliforme), F. ulcerans, F. gonidiaformans, F. mortiferum, F.
naviforme, F. necrogenes, F. russii, and F. varium cause human infections of the head and neck, chest, lung,
liver, and abdomen [19]. F. nucleatum is a well-known oral bacterium that forms typical dental plaque
on human teeth and is involved in periodontal diseases [20]. The greatest characteristic of F. nucleatum
is to adhere to various bacteria and cells. F. nucleatum is a central species in physical interactions
between Gram-positive and Gram-negative species that are likely to be important for biofilm formation,
and it is considered as a bridge for the attachment of commensals that colonize the tooth and epithelial
surface with true pathogens [21,22]. F. nucleatum has two types of substance—fimbriae and non-fimbrial
adhesin—for attaching to other bacteria and cells. These substances contribute to colonization and also
bacterial pathogenesis and infection. Fusobacterium adhesion A (FadA), a fimbrial adhesin protein,
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was recently shown to be required for bacterial attachment and invasion of gingival epithelial and
endothelial cells [23]. FadA has two forms: pre-FadA and mature FadA (mFadA; 111 amino acids).
The pre-FadA (129 amino acids) is a non-secreted protein and is associated with the inner membrane.
The mFadA is a secreted protein and is easily dissociated from bacteria. Mixtures of pre-FadA and
mFadA form high-molecular-weight aggregates, which are required for attachment and invasion of
host cells [24]. FadA is highly conserved among oral fusobacteria, such as F. nucleatum, F. periodonticum
and F. simiae, whereas it is absent in non-oral fusobacterial species, including F. gonidiaformans, F.
mortiferum, F. naviforme, F. russii, and F. ulcerans [23].
Two distinct types of adherence protein have been found in fusobacteria and classified based
on their inhibition mode using either D-galactose or L-arginine [25]. Adherence to predominantly
Gram-negative late-colonizing bacteria, including Porphyromonas gingivalis, Tannerella forsythia, and
Treponema denticola, is associated with galactose-inhibiting (lectin-like) interactions, while adherence to
mainly Gram-positive early colonizing species is associated with arginine-inhibiting (nonlectin-like)
interactions. Three components, a 40–42 kDa major outer membrane porin protein (FomA), and
39.5-kDa and 30-kDa polypeptides, have been suggested as possible adhesins involved in the lectin-like
interbacterial co-aggregation of F. nucleatum [26–28]. These adherent factors of Fusobacterium play
important roles in tumor progression as discussed in the next section.
3. F. nucleatum and Cancer
3.1. F. nucleatum in Colorectal Cancer
Elevated F. nucleatum levels were significantly detected in colon tissue of colon cancer patients
compared with healthy people and F. nucleatum inhabited on colorectal tissues in a half of colon
cancer cases [29,30], suggesting that F. nucleatum may be involved in CRC development. Moreover,
F. nucleatum colonies in primary CRC tissues were also identified in the metastatic liver tissues [31].
Komiya et al. reported that F. nucleatum was detected in both CRC and oral saliva samples, 75% of
which was the same strain [32]. Cumulative clinical evidences suggested that the enrichment of F.
nucleatum might be related to CRC metastasis [29,31,33–35]. Moreover, F. nucleatum was associated with
CRC recurrence and resistance to chemotherapy by activating the autophagy pathway [36]. Thus, F.
nucleatum that may be derived from oral cavity is frequently detected in CRC samples and is suggested
to be involved in malignant behaviors of CRC.
As described above, several reports show the association of F. nucleatum with carcinogenesis
or metastasis of CRC. Kostic et al. reported that intake of F. nucleatum to ApcMIN/+ mice, which
causes gastrointestinal cancer, promoted small and large intestinal tumorigenesis [37]. Moreover,
F. nucleatum was enriched in tumor tissues compared with Streptococcus species [37]. Importantly,
abundance of Fusobacterium was frequently detected in the stool of patients as well as in the adenomas
and CRC tissues [37]. In the intestinal tumor microenvironment, F. nucleatum selectively expanded
myeloid-derived immune cells but not lymphoid immune cells, leading to tumor progression [37].
Moreover, F. nucleatum promotes metastasis of CRC by modulating KRT7-AS/KRT7 [38].
The outer membrane proteins of F. nucleatum, such as FadA and Fibroblast activation protein 2
(Fap2) have been focused as CRC pathogen. E-cadherin acts as a tumor suppressor by modulating
β-catenin pathway [39,40]. Loss or heterogeneous expression of E-cadherin correlated with advanced
stages and poor prognosis of CRC patients [41]. Rubinstein et al. demonstrated that F. nucleatum
attached and invaded into CRC cells via the FadA-mediated interaction with E-cadherin [15]. Moreover,
FadA promotes E-cadherin-mediated CRC tumor growth in xenograft mice via NF-κB activation,
producing proinflammatory cytokines such as IL-6, IL-8, and IL-18 and upregulation of Wnt signaling
gene (Wnt-7a, -7b, and -9a), Myc, and Cyclin D1 [15]. Interestingly, patients with adenoma and
adenocarcinoma in colon had elevated FadA gene expression 10–100 times higher compared to normal
individuals [15].
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Fap2 also plays a critical function in the development of CRC. Fap2, a 390-KDa protein encoded
by the Fap2 gene of F. nucleatum. Fap2 is suggested to be a galactose-sensitive hemagglutinin and
adhesin that is likely to play a role in the virulence of fusobacteria [42]. Fap2 inhibits the immune
cells, such as T cells and NK cells for killing the CRC cells via a immunoreceptor, TIGIT [16].
Moreover, acetylgalactosamine (Gal-GalNAc) is recognized by fusobacterial Fap2, which functions
as a Gal-Gal-NAc lectin [17]. Intravenously injected F. nucleatum localized to mouse CRC tissues in
a Fap2-dependent manner, suggesting that fusobacteria use a hematogenous route to reach colon
adenocarcinomas via interaction between Fap2 and Gal-GalNAc [17]. Interestingly, Gal-GalNAc is
highly expressed in adenocarcinomas including ovary, stomach, colon and lung [43,44]. Although it is
still unclear the role of GalNAc in OSCC, N-acetylgalactosaminyltransferase 3 (GalNAc-T3), which
regulates the critical initial steps of mucin-type O-glycosylation, may play a role in the pathogenesis of
recurrence of early stage of OSCC [45]. These observations suggest that Fap2 of Fusobacterium may
modulate tumor progression by binding to Gal-GalNAc on cancer cells.
Today, there are several therapeutic approaches available with which to modify gut microbiota on
CRC management. To alter the composition and the activity of gut microbiota, several therapeutic
methods, such as fecal microbiota transplantation and administration of prebiotics, probiotics, and
synbiotics, are available for CRC patients [46]. In addition to these methods, oral hygiene managements
for reducing the amount of F. nucleatum may contribute to the prevention of CRC.
3.2. F. nucleatum in Esophageal Cancer
The involvement of F. nucleatum in the development of esophageal cancer has also been reported.
Yamamura et al. reported that DNA levels of F. nucleatum in esophageal cancer tissues were higher than
those in pared adjacent non-tumor tissues [47]. Moreover, esophageal squamous cell carcinoma (ESCC)
tissues contained more Fusobacterium (3.2% vs. 1.3%) and less Streptococcus (12.0% vs. 30.2%), compared
to the non-tumor tissues [48]. Importantly, higher DNA levels of F. nucleatum in ESCC patients were
significantly associated with cancer-specific survival [47], predicted poor recurrence-free survival,
and poor response to neoadjuvant chemotherapy [49]. In addition, C-C Motif Chemokine Ligand 20
(CCL20), which plays crucial roles in cell proliferation and migration, is significantly upregulated in F.
nucleatum-positive esophageal cancer tissues [47]. Thus, F. nucleatum is involved in the development of
colorectal and esophageal cancers.
3.3. Fusobacterium Species and Oral Cancer
There are many reports showing that Fusobacterium were detected in OSCC tissues [50,51].
The ratio between aerobes and anaerobes within the biofilms on the surfaces of OSCC tissues was
approximately 1:2, whereas that in the healthy control was 2:1, indicating that OSCC surfaces provide
an important reservoir for anaerobic bacteria [52]. F. nucleatum subsp. polymorphum was the most
significantly overrepresented species in OSCC compared to the control group with deep-epithelium
swabs [53]. Perera et al. also reported that the Fusobacterium was enriched in OSCC biopsy compared to
fibroepithelial polyp as a control [54]. Moreover, significantly greater bacterial diversity was observed
in the swab of OSCC sites than that of normal sites [55]. Thus, distribution of bacteria including
Fusobacterium in OSCC tissues may be distinct from that in healthy oral mucosal tissues. Yang et al.
reported that F. periodonticum and several bacteria in oral rinse samples were associated with OSCC,
and they progressively increased in abundance from stage I to stage IV [56].
Fusobacterium can invade into epithelial cells. Compared to P. gingivalis, wild-type F. nucleatum
12,230 remarkably adheres and invades into human gingival epithelial cells (HGECs) [57]. Interestingly,
the spontaneous mutant of F. nucleatum was unable to invade into HGECs, suggesting the requirement
for bacterial components to their invasion [40]. Moreover, glucose inhibition assay shows that lectin-like
interactions are involved in the attachment of F. nucleatum to OSCC cells [57]. Furthermore, infection
of F. nucleatum in human epithelial cells promotes cellular migration, possibly via stimulation of
Etk/BMX, S6 kinase p70, and RhoA kinase and increases the production of MMP-13 (collagenase 3)
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via the activation of mitogen-activated protein kinase p38 [58]. However, the detailed mechanisms
of adhesion of Fusobacterium in OSCC cells and F. nucleatum-mediated invasion of OSCC cells is still
unclear. Nevertheless, the fact that F. nucleatum is abundant in the oral cavity of OSCC patients seems
to be important in the tumorigenesis and/or the progression of oral cancer.
Several reports show the involvement of F. nucleatum in tumorigenesis and development of
OSCC. Gallimidi et al. demonstrated that chronic intake of P. gingivalis and F. nucleatum promoted
tumor progression in a 4-nitroquinoline-1-oxide (4NQO)-induced mouse tongue cancer model [59].
The infected group showed larger and more invasive tumors with increased expression of cyclin D1,
IL-6, and phospho-STAT3. Moreover, co-culture with P. gingivalis and F. nucleatum upregulated IL-6
expression in OSCC cells, whereas these effects was not caused by F. nucleatum alone [59]. These
findings suggest that exposure of oral epithelial cells to P. gingivalis/F. nucleatum triggers TLR signaling,
resulting in IL-6 production that activates STAT3 which in turn induces important effectors driving
growth and invasiveness of OSCC cells, such as cyclin D1.
It is known that epithelial-to-mesenchymal transition (EMT) in cancer cells is associated with
invasion, metastasis, stemness, and resistance of therapy [60]. Recently, F. nucleatum promotes cell
migration and EMT by upregulating mesenchymal markers, including N-cadherin, Vimentin, and
SNAI1 in noncancerous human immortalized oral epithelial cells and OSCC cell lines [61]. As EMT is
important event of tumor progression and malignant behaviors, it is worth investigating whether F.
nucleatum is involved in EMT in OSCC cells. Recently, it has been reported that partial-EMT (p-EMT)
that partially combines epithelial and mesenchymal features, is involved in tumor progression and
metastasis [62,63]. We previously reported that SERPINE1, ITGA5, TGFBI, P4HA2, CDH13, and LAMC2
can be a prognostic marker among p-EMT genes [64]. In our preliminary finding, co-culture with
F. nucleatum promoted invasion of OSCC cells with upregulation of p-EMT genes [65]. We are now
investigating the detailed mechanism of F. nucleatum–driven p-EMT in OSCC.
Inflammasomes are multiprotein complexes that regulate immune processes in response
to infections and tissue damage. Inflammasomes mediate the processing of the two most
important inflammatory cytokines, pro-interleukin-1β (IL-1β), and pro-IL-18 to their active forms.
The inflammasome is formed by the apoptosis-associated speck-like protein containing a CARD
(ASC), procaspase-1, and a sensor protein, which is either a NOD-like receptor (NLR) or an absent in
melanoma 2 (AIM2)-like receptor. IL-1βplays a pro-tumorigenic role and enhances the aggressiveness of
OSCC [66]. Aral et al. reported that F. nucleatum infection in OSCC cells promotes AIM2 inflammasome
expression [67]. In addition, F. nucleatum potentially upregulated IL-1β expression, but downregulated
POP1 which controls NLRP3 inflammasome activation by targeting ASC. Especially in the oral cavity,
it is reported that the presence of nanoparticles released from dental metal alloy activates NLRP3
inflammasome in human oral keratinocytes, resulting in the development of potentially malignant oral
disorders [68]. As TRIM16, which enhances IL-1β production, is also upregulated by F. nucleatum, F.
nucleatum may play a role by dysregulating inflammasomes and their modulators in OSCC.
Bacterial infection influences genomic stability and integrity by causing DNA damage, which
increases the possibility of tumor initiation and development. Recently, it has been reported that F.
nucleatum infection in OSCC cells causes DNA damage via Ku70/p53 pathway [69]. Although Ku70 is
involved in the non-homologous end joining (NHEJ) pathway of DNA repair via binding to DNA
double-strand break ends, the detailed mechanism of the association between F. nucleatum infection
and Ku70 is still unclear.
It has been shown that there are specific associations among bacteria within dental plaque by
cluster analysis using subgingival plaque samples [70,71]. As shown in Figure 1, various bacteria exist
as shown in the pyramid. F. nucleatum is in the middle of pyramid. Among the species in the middle
of pyramid, F. nucleatum is dominant in the dental biofilm at a later stage of plaque formation. As
described above, Fusobacterium infection affects the tumorigenesis and development of OSCC through
various responses (Figure 1). However, the target molecules of Fusobacterium are still unknown. Further
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studies will be required for clarifying the evidence of Fusobacterium involvement in tumorigenesis and
development of OSCC.Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 6 of 10 
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stage. Then, complex species in the middle of pyramid becomes numerically more dominant later and is
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more dominant at late stages in plaque development. Among them, Fusobacterium species may adhere
with oral keratinocyte or oral cancer cells via interaction between FadA/Fap2 and E-cadherin. This
interaction may induce carcinogenesis and cancer progression.
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